Sponsor content
19 result(s) found, displaying 11 to 19
-
Prescription medicine decision summaryTGA decision: Xembify (normal immunoglobulin human) is approved to treat primary immunodeficiency diseases (PID).
-
Australian public assessment report (AusPar)VeraSeal (human fibrinogen and human thrombin) for the supportive treatment of hemostasis.
-
Prescription medicine registrationActive ingredients: human immunoglobulin G.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Grifols Australia Pty Ltd - General laboratoryware IVDs.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Grifols Australia Pty Ltd - Instrument/analyser IVDs.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Grifols Australia Pty Ltd - Analyser software IVDs.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Grifols Australia Pty Ltd - Immunohaematology blood grouping antisera IVDs.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Alpha-1 proteinase inhibitor
-
Cancellation by sponsorRequested by Grifols Australia Pty Ltd